Last checked at 11 Oct 2010 14:30
11 October 2010
Immupharma plc
ADDITIONAL LISTING AND TOTAL VOTING RIGHTS
PICTET INCREASE HOLDING TO OVER 3%
ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company"), the specialist discovery and development pharmaceutical company announces that following the exercise of options held by the liquidators to Dawnay Day Corporate Finance Limited, application has been made to the London Stock Exchange for the admission of 441,000 new ordinary shares of 10 pence each in the Company to trading on AIM. It is expected that these new ordinary shares, which will rank pari passu with the existing ordinary shares of the Company, will be admitted to trading on 12 October 2010.
Following the allotment of the new ordinary shares, the Company's issued share capital will consist of 81,532,463 Ordinary Shares of 10p each which entitle the holder to one vote per share. Therefore, the total number of voting rights is 81,532,463.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules.
The Company is also pleased to announce that Pictet Overseas Trust Corporation Limited have increased their stake in Immupharma to 3.02%.
Commenting on the developments, Chairman, Richard Warr, said:
"We are delighted that Pictet have increased their shareholding in ImmuPharma in excess of 3% and are pleased to have the continued support of such a prestigious Swiss bank."
For further information, please contact:
ImmuPharma PLC:
Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080
Richard Warr, Chairman
Tracy Weimar, VP, Operations
Buchanan Communications
Lisa Baderoon, Mark Court +44 20 7466 5000
Panmure, Gordon & Co., NOMAD & Broker
Andrew Burnett +44 20 7459 3600
Rakesh Sharma
Execution Noble & Co, Joint Broker
James Bromhead +44 20 7456 9191
Richard Crawley